All In Biotech

Drug Trial Radar · NCT04758767

CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma

A Phase 1 Dose Escalation and Expansion Study of CID-103, an Anti-CD38 Antibody, in Patients With Previously Treated Relapsed or Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Apr 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Actual

Start

Mar 22, 2021

Primary completion

Jan 19, 2023

Study completion Jan 19, 2023

Sponsor

Lead sponsor
CASI pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Feb 17, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients with relapsed/refractory multiple myeloma will be enrolled in a dose-escalation phase receiving monotherapy CID-103. Once the recommended CID-103 dose and infusion duration is known, additional patients will be enrolled in an expansion phase consisting of two cohorts (anti-CD38 pretreated, and anti-CD38 treatment naïve). Patients will be treated until disease progression or unacceptable toxicities.

Conditions

  • Multiple Myeloma

Interventions

  • CID-103Drug

    anti-CD38 antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventsTime frame: approximately 18 months after study start

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • CHU de Nantes - Hôpital Hôtel-Dieu

    Nantes, France

  • CHU Rennes - Pontchaillou

    Rennes, France

  • Gustave Roussy Cancer Center

    Villejuif, France

  • Sarah Cannon

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.